Palbociclib, a CDK 4/6 inhibitor, was approved by the Food and Drug Administration (FDA) in February 2015 for the treatment of estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy in postmenopausal women. Here, ESR1 is linked to breast carcinoma.